Surgical management of hypertrophic obstructive cardiomyopathy Early and late results by Heric, Blaine et al.
SURGICAL MANAGEMENT 
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Early and late results 
From 1975 through 1993, 178 patients underwent surgical management of
hypertrophic obstructive cardiomyopathy. Operations included isolated septal 
myectomy (n = 95), septal myectomy and coronary artery bypass grafting (n = 
41), septal myectomy plus a valve procedure (n = 25), septal myectomy, valve 
procedure, and coronary artery bypass grafting (n = 14), and mitral valve 
replacement without septal myectomy (n = 3). Recent myectomy results were 
monitored with transesophageal chocardiography. After initial myectomy, 32 
patients (20%) underwent a second pump run for more extensive myectomy 
only (n = 22), mitral valve replacement only (n = 5), or both (n = 2). 
In-hospital mortality was 6% (n = 11) and 4% (n = 6) for patients undergoing 
septal myectomy or septal myectomy plus coronary artery bypass grafting, 
respectively. Heart block occurred in 17 patients (10%). Left ventricular 
outflow tract systolic gradients decreased from a mean of 93 mm Hg to 21 mm 
Hg after myectomy. Late survival was 86% and 70% at 5 and 10 postoperative 
years, respectively, and 93% and 79% for patients undergoing septal myectomy 
alone or septal myectomy plus coronary artery bypass grafting, respectively. 
Only 3 of 131 in-hospital survivors of septal myectomy or septal myectomy plus 
coronary artery bypass grafting died late cardiac deaths, for a yearly mortality 
of 0.6%. However, the 5-year late survival of patients undergoing valve 
operation plus septal myectomy was 51%, and multivariate t sting confirmed 
the adverse influence on late survival (p = 0.008), as well as adverse influences 
of increasing age (p = 0.016) and return to cardiopulmonary b pass for mitral 
valve replacement (p = 0.038). At follow-up 136 patients (94%) had New York 
Heart Association class I or II symptoms. For patients with hypertrophic 
obstructive cardiomyopathy, sePtal myectomy alone or in combination with 
coronary artery bypass grafting produces effective symptom relief, excellent 
long-term survival, and a low risk of late cardiac death. (J THORAC CARDIO- 
VASC SURG 1995;110:195-208) 
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flow tract. This obstruction is associated with abnor- 
mal systolic motion of the anterior mitral leaflet. 
Treatment of patients with symptomatic conditions 
includes beta and calcium channel blockers, 1-4 anti- 
arrhythmics,5, 6 and, recently, dual chamber pac- 
ing. 7-8 Surgical myectomy to relieve outflow obstruc- 
tion is reserved for patients who have significantly 
symptomatic onditions while receiving medical 
therapy, those with associated surgical cardiac dis- 
ease, and younger patients with mildly symptomatic 
conditions and a history of syncope. 
Transaortic septal myectomy 9 has been the pri- 
mary surgical approach at our institution over the 
last 18 years. Our increasing experience with this 
technique and emerging controversy 1~ over the role 
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Table I. Preoperative and postoperative gradient, 
MR, and SAM 
Preop. Postop. 
(n) (n) 
Maximum gradient (ram Hg) 
0 -25 4 97 
26-50 7 30 
51-75 39 2 
76 -100 74 3 
101-200 46 i 
Total 170 133 
MR 
None 15 
1+ 36 
2+ 43 
3 + 48 
4+ 12 
Total 154 
SAM 
None 13 67 
Mild 19 46 
Moderate 75 6 
Severe 24 2 
Total 131 121 
MR, Mitral regurgitation; SAM, systolic anterior motion; Preop., preoper- 
ative; Postop., postoperative. 
of surgical myectomy and dual chamber pacing 
therapy prompted us to review our early and late 
results. 
Patients and methods 
A consecutive s ries of 178 patients undergoing surgical 
treatment of hypertrophic cardiomyopathy, primarily sep- 
tal myectomy alone, or myectomy in combination with a 
valve or coronary procedure at the Cleveland Clinic 
Foundation from 1975 through 1993 was reviewed. Over 
half of the procedures were performed over the last 3 
years of this period. Patients with congenital subaortic 
membrane were excluded. Clinical information was de- 
rived from a retrospective individual chart review and the 
Cleveland Clinic Cardiovascular Information Registry. 
One half (n = 89) of our patient population was male, 
and 70% were in their sixth to ninth decade of life. Eight 
percent (n = 11) had a documented family history of 
hypertrophic cardiomyopathy. Ninety percent of the pa- 
tient population (n = 165) had normal or mildly impaired 
left ventricular function, and 36% (n = 58) had significant 
surgical coronary artery disease. Ten patients (6%) un- 
derwent reoperation, and four (3%) required emergency 
operative intervention. 
Preoperative diagnosis was based on clinical history, 
echocardiographic examination, and cardiac catheteriza- 
tion. Preoperative medications included calcium channel 
blockers in 77 (61%), beta blockers in 78 (62%), amioda- 
rone in seven (6%), and norpace in seven (6%). The most 
common symptoms were dyspnea in 103 patients, followed 
by angina (n = 87), syncope (n = 55), congestive heart 
failure (n = 39), atrial arrhythmias (n = 49), and ventric- 
ular arrhythmias (n = 11). Individual patients typically 
had multiple symptoms. Syncope includes patients with 
near-syncopal symptoms. 
Preoperative gradients were determined at cardiac 
catheterization or at echocardiography and were deter- 
mined with and without provocation. The preoperative 
and postoperative gradients and the degree of mitral 
regurgitation (MR) and systolic anterior motion of the 
anterior mitral leaflet are summarized in Table I (The 
gradient listed in Table I is the larger of either the 
gradient at rest or with provocation. When only one value 
was available, that gradient is listed.) The degree of 
postoperative MR was not consistently available on ret- 
rospective review and is not included in Table I. 
Surgical technique. Standard cardiopulmonary b pass 
with systemic moderate hypothermia, LV venting, and 
either blood or crystalloid antegrade and/or retrograde 
cardioplegic solution was used. Since 1984 intraoperative 
echocardiography as guided transaortic resection of the 
region of septal hypertrophy. The echocardiographic te h- 
niques have been previously reported by our group al and 
others.lZ. 13 After an oblique transverse aortotomy, the 
aortic cusps were retracted to expose the subvalvar hyper- 
trophied septum. The involved septal area is beneath the 
right coronary cusp and is characterized by a thickened 
and fibrotic endocardial plaque from contact with the 
anterior leaflet of the mitral valve. 12 Two parallel incisions 
in the direction of the left ventricular apex are made 
encompassing this area of septal hypertrophy, and a 
muscle bar 1 cm in depth and 1 to 2 cm in width that 
extends 3 to 5 cm toward the apex is resected. The 
resection is extended toward the LV apex until the bases 
of the papillary muscles are visualized. This intraoperative 
visual localization is corroborated by intraoperative echo- 
cardiography, which allows precise localization of this 
area of septal hypertrophy. In particular the relation of 
the obstructing septum to the aortic valve anulus, the 
apical extent of hypertrophy and mitral valve septal 
contact, and maximal septal thickness are useful echocar- 
diographic parameters in guiding precise surgical resec- 
tion. On completion of the septal myectomy and any 
associated procedures, patients were weaned from cardio: 
pulmonary bypass, and echocardiographic determination 
Of the LV outflow tract (LVOT) gradient, with and 
without progressively higher doses of isoproterenol (Isu- 
prel), was performed. The presence of an LVOT gradient 
greater than 50 mm Hg, with or without provocation, or 
greater than moderate MR was generally an indication for 
a return to bypass and either a more extensive myectomy 
or mitral valve replacement (MVR). 
The operative procedures performed are listed in Table 
II. Seventy-six percent of patients underwent septal my- 
ectomy alone or in combination with coronary artery 
bypass grafting (CABG). Twenty-one patients underwent 
a ~nitral valve procedure during initial hospitalization, two 
of whom underwent MVR on reoperation. Of these 21 
patients who underwent a mitral valve procedure during 
their initial hospitalization, 16 had an MR grade of 3 to 
4+ before the operation. Ten of these patients underwent 
MVR at initial operation with and without associated 
septal myectomy. The origin of MR in this group was 
rheumatic in four patients, bacterial endocarditis n three, 
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Table II. Operations performed (n = 178) 
Myectomy only 95 (54%) 
Myectomy/CABG 41 (23%) 
Myeetomy/valve 25 (14%) 
Mitral 9 (5%) 
Aortic 12 (7%) 
Mitral/Aortic 3 (2%) 
Mitral Tricuspid 1 (1%) 
Myectomy/eABG/valve 14 (8%) 
Mitral 4 (2%) 
Aortic 9 (5%) 
Mitral/aortic 1 (1%) 
Mitral valve replacement 3 (2%) 
Mitral 2 (1%) 
Mitral/aortic 1 (1%) 
and cleft mitral valve, papillary fibroelastosis, and degen- 
erative myxomatous mitral valve disease in the remaining 
three patients. Four patients underwent mitral valve re- 
pair. The origins of MR in these four patients included 
rheumatic, cleft posterior mitral leaflet, myxoma, and, in 
the fourth patient, the origin was unclear. The remaining 
seven patients underwent MVR because of the presence 
of a persistent postmyectomy gradient or significant MR. 
Six of these seven patients had normal mitral valves, and 
one had a myxomatous valve. 
Clinical follow-up was obtained in 175 of 178 patients 
(98%) by direct telephone interview with individual pa- 
tients and their referring physicians. 
Statistical analysis. The mean period of follow-up 
was 44 months (standard eviation 3.9 months). Means 
and percentages were based on the set of nonmissing 
observations. Preoperative, intraoperative, and postop- 
erative factors were considered as potential predictors 
of early and late death. Risk factors that were signifi- 
cant (p < 0.05) or nearly significant univariate predic- 
tors of death were also considered for inclusion in 
multivariate models of death. In-hospital mortality was 
analyzed for all patients, and late death was studied in 
the cohort of hospital survivors. Nonparametric survival 
curves were based on Kaplan-Meier estimates, and the 
p values for these curves were based on the log-rank 
test. Semi-parametric models of late death were based 
on a Cox regression analysis. Univariate and multivari- 
ate models of hospital death involved the logistic 
regression technique. Separate models including and 
excluding postoperative factors were used; p values 
based on Wald X 2 statistics were used to evaluate 
significance in these models. 
Results 
Hospital mortality. Hospital mortality was 6% 
overall, 4% for patients undergoing myectomy 
alone, and 5% for those undergoing myectomy and 
CABG. Addition of a valve procedure to myectomy 
increased the mortality to 8%. Patients requiring a 
combined myectomy, CABG, and valve procedure 
Table III. Causes of hospital and late death 
Late death (n = 18) 
Hospital Myectomy with 
death or without 
(n = 11) CABG Valve* 
Cancer 0 4 
Nondocumented 0 1 
(probable cardiac) 
LV failure 3 1 
CVA 3 0 
Sudden cardiac death 1 1 
.Renal failure 0 0 
Endocarditis 1 0 
RV rupture 1 0 
LV rupture 1 0 
Bleeding 0 1 
Sepsis 0 0 
Multiorgan failure 1 0 
1 
1 
1 
2 
0 
0 
0 
1 
0 
CVA, Cerebrovascular accident; RV, right ventricular. 
*Patients who underwent a valve procedure with or without associated 
myectomy orCABG. 
Table IV. Risk of hospital death 
Odds p Confidence 
Risk factor ratio Value interval 
Univariate logistic regression 
models of hospital death* 
Aget 1.9 0.029 1.1, 3.5 
Amiodarone 7.2 0.029 1.2, 41.8 
Functional elass:~ 2.8 0,054 1.0, 8.2 
Valve operation 2.9 0.090 0.8, 10.1 
Multivariate logistic regression 
model with only preopera- 
tive predictors 
Amiodarone 6.9 0.040 1.1, 43.2 
Aget 1.9 0.043 1.0, 3.6 
Valve operation 2.8 0.117 0.8, 10.5 
*With preoperative and operative predictors of hospital death. 
tOdds ratio for age represents increased odds of hospital death for every 
10 years of age. 
gFunetiona! class odds ratio represents the increased odds for each 
increased functional class level (I, II, III and IV). 
had a mortality of 21%. Eight of the 11 hospital 
deaths occurred in female patients. The causes of 
in-hospital mortality and late deaths are outlined in 
Table III. Univariate logistic regression analysis of 
hospital deaths (Table IV) showed age and preop- 
erative amiodarone usage to be significant predic- 
tors of in-hospital mortality. Hospital mortality was 
10% in patients over 60 years of age compared with 
1.3% in those under 60 years of age. Amiodarone 
usage increased mortality to 29% compared with 
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Table V. Postoperative complications* 
Complete heart block 17 
Return to operating room 22 
Bleeding 13 
MVR 2 
Redo myectomy 1 
Redo myectomy/MVR 1 
LV rupture 2 
RV rupture 1 
Pericardial effusion 1 
Atrial arrhythmias 46 
Ventricular arrhythmias 13 
Respiratory 13 
Renal 9 
CVA 5 
Wound 3 
RV,, Right ventricular; CVA, cerebrovascular accident. 
*A total of 128 complications i  87 patients. 
2% in untreated patients. New York Heart Associ- 
ation functional class (p = 0.054) and valve opera- 
tion (p = 0.090) tended toward statistical signifi- 
cance. A multivariate logistic regression model of 
hospital deaths also showed age and amiodarone 
usage to be statistically significant preoperative pre- 
dictors. Valve operation was less strongly associated 
with hospital death and not statistically significant. 
Hospital morbidity. Postoperative complications 
are listed in Table V. The overall incidence of 
complete heart block was 10%. Of the l7 cases, 10 
occurred in the isolated myectomy surgical group, 
and six developed in patients undergoing a con- 
comitant valve procedure. One patient underwent 
deliberate surgical interruption of atrioventricular 
conduction to produce complete heart block and 
control malignant supraventricular arrhythmias. 
The incidence of complete heart block in the patient 
undergoing isolated myectomy requiring a second 
pump run was 30%, which is significantly higher 
(p = 0.005) than the 6% incidence in the myectomy 
group undergoing a single pump run. Four patients 
underwent five in-hospital reoperations which in- 
cluded MVR in two, redo myectomy and MVR in 
one, and isolated myectomy for a persistent residual 
gradient in the remaining patient. 
Hemodynamics. The mean maximal preoperative 
LVOT gradient measured in 170 patients at rest or 
with provocation was 93 mm Hg and decreased toa 
mean of 21 mm Hg in the 133 patients in whom 
measurements were recorded. In the immediate 
postoperative period, six patients had persistent 
measured gradients greater than 50 mm Hg, eight 
had moderate to severe systolic anterior motion of 
the anterior mitral leaflet (SAM), and 17 had MR 
grade 2 to 3 +. Statistical analysis failed to show any 
relationship between persistent gradient, MR, or 
SAM and hospital morbidity, mortality, late morbid- 
ity or mortality, or return to New York Heart 
Association functional class III or IV symptom 
status. Thirty-two patients returned to cardiopulmo- 
nary bypass at their initial operation because of 
either a persistent LVOT gradient or significant MR 
and SAM. Twenty-two patients underwent repeat 
myectomy, and five patients underwent MVR alone 
or in combination with myectomy. Of the 60 patients 
with MR grade 3 to 4+ on preoperative echocardi- 
ography, 16 underwent MVR. Five patients who 
required MVR did not have significant MR docu- 
mented before the operation. Ten were performed 
as planned on the initial pump run. Five were 
performed on return to cardiopulmonary b pass 
because of persistent MR after myectomy, and two 
were performed at reoperation during the same 
hospitalization. No late MVRs were performed in 
patients with grade 3+ or 4+ MR noted before the 
operation. 
Late deaths. Fig. 1 shows overall survival and 
event-free survival. Fig. 2 shows a late survival at 10 
years of 79% for myectomy with or without CABG, 
'compared with 26% when a valve procedure is 
added. The causes of late death are listed in Table 
III. Two patients undergoing myectomy, with or 
without concurrent CABG, experienced sudden 
death on long-term follow-up, and one died of 
progressive LV failure. 
Predictors of late death with the use of univariate 
and multivariate Cox regression models are listed in 
Table VI. For age, the risk ratio rates represent the 
increased risk for every 10 years of age. For MR, the 
risk ratio represents the increased risk for each 
increased level of MR (1+, 2+, 3+, etc.). Strong 
predictors of late death included concomitant valve 
operation, increasing age, a history of syncope or 
near-syncope, complete heart block, and the perfor- 
mance of MVR when initial myectomy resulted in 
either a significant residual gradient or MR. Twelve 
of the 19 late deaths and two thirds of all deaths 
occurred in women. 
Functional status/late events. Preoperative and 
follow-up functional class is shown in Table VII. Of 
the two patients who were in functional class 1 
before the operation, one underwent "prophylactic" 
septal myectomy before a planned neurosurgical 
procedure, and the other was a young child with a 
large gradient and history of syncope. Nine patients 
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Fig, 1. Overall ate survival and event-free survival for 167 in-hospital survivors. Late survival at 5 and 10 
postoperative y ars was 86% and 70%. Event-free survival at 5 and 10 years was 66% and 35%. The 
numbers of patients remaining in the survival sample at 2, 4, 6, 8, and 10 years was 83, 53, 34, 18, and 6, 
respectively. The numbers of patients remaining in the event-free sample at 2, 4, 6, 8, and 10 years was 95, 
63, 39, 24 and, 8, respectively. Error bars are - standard eviation. 
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Fig. 2. Late survival by procedure of 167 in-hospital survivors. Survival of the septal myectomy (SM) with 
or without coronary artery bypass grafting (CABG) group at 5 and 10 years was 93% and 79%, respectively, 
compared with 51% and 26% in the group undergoing a valve procedure. The respective numbers of 
patients remaining in the sample for the myectomy with or without CABG group at 2, 4, 6, 8, and 10 years 
were 80, 15, 35, 22, and 8. The respective numbers remaining for the valve group at 2, 4, 6, 8, and 10 years 
were 15, 8, 4, 21, and 0. Error bars are _+ standard eviation. 
were in functional class III or IV on long-term 
follow-up. Univariate and multivariate analyses with 
preoperative, operative, and postoperative ariables 
could not show any statistically significant predictors 
of this treatment failure group. The 108 late events 
in 75 patients are listed in Appendix A. Six patients 
underwent seven late reoperations that included 
CABG in two, and MVR/aortic valve replacement, 
tricuspid valve replacement, MVR, and ventricular 
septal defect repair in the remaining four patients. 
Fig. 3 shows the statistically significant difference 
in event-free survival between those patients under- 
going myectomy with or without CABG and those 
undergoing a concomitant valve procedure. 
Discussion 
Widespread use of two-dimensional echocardiog- 
raphy has led to increasing clinical recognition of 
the obstructive form of hypertrophic cardiomyopa- 
thy. This recognition has been reflected in our 
progressive xperience with the surgical manage- 
ment of this morphologically diverse disease during 
the last 5 years. The variable clinical expression 
and natural history of hypertrophic obstructive 
cardiomyopathy and institution-specific referral 
patterns has complicated comparison of surgically 
treated patients with those treated medically. As a 
result, controversy remains over (1) the role of 
surgical myectomy compared with drug arid pace- 
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Table VI. R&k of late death 
Odds p Confidence 
Risk factor ratio Value interval 
Univariate Cox regression 
models of late death 
Valve operation 6.6 <0.001 2.6, 16.6 
RTB/MVR* 22.6 <0.001 6.5, 78.2 
Age 2.3 0.001 1.4, 3.8 
CHB 4:8 0,008 1.5, 15.6 
Blood used 6.2 0.015 1.4, 26.9 
Syncope 3.2 0.015 1.3, 13.5 
MR 1.6 0.056 1.0, 2.4 
CVA 7.3 0.057 0.9, 56.0 
Multivariate model with preop., 
op., and postop, predictors 
CHB 9.5 0.00i 2.6, 35.0 
Valve operation 4.7 0.008 1.4, 15.3 
Age 2.0 0.010 1.2, 3.1 
Syncope 4.0 0.020 1.2, 12.6 
RTB/MVR* 5.4 0.038 1.1, 26.8 
RTB, Return to bypass; CHB, complete heart block; CVA, cerebrovascular 
accident; preop., preoperative; postop., postoperative. 
*Patients who after initial rayectomy required return to cardiopulmonary 
bypass and MVR with and without septal myectomy. 
maker therapy in the management of hypertro- 
phic obstructive cardiomyopathy, (2) identifica- 
tion of patient subgroups at higher operative risk, 
(3) long-term functional results and the influence, 
if any, of surgical procedures on the incidence of 
sudden death, (4) the role of intraoperative echo- 
cardiography and the long-term significance of 
postoperative echocardiographic findings, and (5) 
the role of MVR. 
Hospital mortality. Our overall 6% hospital mor- 
tality and 4% to 5% mortality for patients undergo- 
ing septal myectomy with or without CABG is 
comparable with that reported in other surgical 
series.Z, 24-20 Only increasing age and preoperative 
amiodarone usage were significant multivariate pre- 
operative predictors of hospital death. Although 
concomitant valve operation did riot predict hospital 
mortality, the addition of valve operation to septal 
myectomy with CABG increased perioperative mor- 
tality to 21%. The variation in reported mortality 
rates is primarily related to patient age and the 
performance of concomitant surgical procedures. 
Mohr and associates 21 reported no operative mor- 
tality in 47 consecutive patients under 40 years of 
age, 43 of whom underwent isolated myectomy. 
Cohn, Trehan, and Collins, 16 likewise, reported zero 
mortality in 32 older patients (mean age 55 years) 
undergoing isolated myectomy. The adverse influ- 
ence of age and concomitant procedure was empha- 
Table VII. New York Heart Association functional 
class (n) 
Preoperative At follow-up 
I 2 103 
II 29 33 
III 113 8 
IV 4 1 
sized by the Mayo Clinic group 14 who reported 
15.6% mortality in patients older than 65 years of 
age and 11.4% for patients undergoing an additional 
revascularization r valve procedure. Similarly, a 
recent large series from Dusseldorf 15reported 2.9% 
hospital mortality in 272 patients undergoing iso- 
lated septal myectomy versus 10.9% in 92 patients 
undergoing simultaneous procedures. However, the 
adverse influence of concomitant CABG reported 
by the National Institutes of Health group, who 
describe a 2.7% operative mortality for isolated 
myectomy compared with 18% in those undergoing 
simultaneous CABG, was not apparent in our 
study. 22 The National Institutes of Health group 
concluded that their operative mortality was higher 
because of an increased incidence of ventricular 
septal defect (21%) potentially because of septal 
ischemia in the presence of coronary artery disease. 
Our mortality of 5% in patients undergoing simul- 
taneous myectomy and CABG was nearly equivalent 
to that for myectomy alone. We did not encounter a 
higher incidence of ventricular septal defect. 
The antiarrhythmic efficacy and negative inotro- 
pic effects of amiodarone have led to its use in the 
management of hypertrophic obstructive cardiomy- 
opathy with varying results. 6'23 One group has found 
an increased incidence of sudden death in patients 
treated with amiodarone. 23 The adverse ffects of 
preoperative amiodarone in the surgical manage- 
ment of hypertrophic obstructive cardiomyopathy 
has been reported by the National Institutes of 
Health group 24 who described an increased inci- 
dence of postoperative pulmonary, hepatic, and low 
cardiac output complications in treated patients. 
Seven patients were treated with amiodarone, and 
two deaths occurred among this seven. Of our two 
patients treated with amiodarone who died, one 
clearly had a sudden cardiac death 13 hours after the 
operation. The other patient had markedly elevated 
transaminase levels after the operation and diffuse 
hepatic necrosis on autopsy. These two patient 
deaths may have been directly related to amioda- 
rone usage. 
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Fig. 3. Event-free survival by procedure (events listed in Appendix A) of 167 in-hospital survivors. 
Event-free survival of the septal myectomy(SM) with or without coronary artery bypass grafting (CABG) 
group at 5 and 8 years was 74% and 52%, respectively, compared with 36% and 15% in the group 
undergoing a valve procedure. The respective numbers of patients remaining in the sample in the 
myectomy with or without CABG group at 2, 4, 6, 8, and 10 years were 71, 48, 30, 16, and 6. The respective 
numbers of patients in the valve group at 2, 4, 6, 8, and 10 years were 12, 5.4, 2. and 0. Error bars are - 
standard eviation. 
Complications. The 10% incidence of complete 
heart block in our series is higher than the 5% 
reported by Maron and others. 1' 24, 25 In the isolated 
myectomy group its occurrence is associated with 
return to cardiopulmonary b pass and redo myec- 
tomy. In addition, the presence of complete heart 
block was a strong predictor of reduced late survival 
on multivariate analysis. This association of com- 
plete heart block and need for repeat myectomy may 
reflect he presence of more severe septal hypertro- 
phy in this group and subsequent need for a more 
aggressive myectomy leading to atrioventricular 
node injury. Although our higher incidence of com- 
plete heart block may reflect the degree of septal 
hypertrophy in those patients affected, it may also be 
a marker for the thoroughness of echocardiographi- 
cally guided septal resection, durable relief of LV 
outflow obstruction, and excellent long-term symp- 
tom relief we have observed. 
Postoperative iatrogenic ventricular septal defect 
has been reported in 3% of patients by Kirklin and 
Barratt-Boyes, 2~this complication occurred in only 
one of our patients in the early part of our experi- 
ence before the routine use of echocardiography. 
Intraoperative two-dimensional echocardiography is 
instrumental in guiding the appropriate amount and 
location of septal resection and may be partly re- 
sponsible for the low incidence of this complication 
observed 'in our population. 
In-hospital reoperation was necessary in four 
patients: one underwent extended myectomy, two 
underwent MVR, and one underwent both MVR 
and myectomy. Of six patients undergoing late 
reoperation, none required repeat myectomy for a 
persistent gradient, although two required MVR. 
This 1.2% incidence of late MVR and absence of 
late repeat myectomy compares favorably with the 
late reoperation experience from the National Insti- 
tutes of Health. 26 On long-term follow-up of 535 
patients undergoing septal myectomy, they report 23 
patients (4.3%) who required late reoperations that 
included MVR in 11 and repeat myectomy in 12. 
Significant aortic insufficiency requiring late aor- 
tic valve replacement occurred in one patient. We 
did not review all incidences of mild-to-moderate 
aortic insufficiency which occurred in 54% of 67 
patients followed up by Sasson and associates. 27 The 
National Institutes of Health group 28 reported a 4% 
incidence of significant late aortic insufficiency in 
525 patients after myectomy. Six of their 12 patients 
required aortic valve replacement. 
Late mortality. Late survival for our entire group 
was 86% and 70% at 5- and 10-year follow-up, 
respectively, and 93% and 79% for patients under- 
going septal myectomy with or without CABG. Only 
3 of 131 in-hospital survivors of septal myectomy 
with or without CABG died late cardiac deaths, for 
a yearly mortality of 0.6%. This late mortality com- 
pares favorably with natural history studies which 
report mortality rates of 3% to 6%/year. 1'29 Fifty-six 
percent of our patient group was older than 60 years 
of age and may have had a distinct form of hyper- 
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trophic obstructive cardiomyopathy 3~ with a more 
favorable natural history than that in younger pa- 
tients. The Mayo Clinic has followed up a group of 
95 patients over the age of 65 for a median duration 
of 4.2 years and found survival not significantly 
different from that in an age- and gender-matched 
control group. 31 A literature review by Seiler and 
associates 17 of 12 medical series from 1974 through 
1990 including 869 medically treated patients, with a 
follow-up ranging from 1.2 to 9.1 years, reported 
yearly mortality rates ranging from 0.5% to 6%. 
They review five surgical series with reported mor- 
tality rates of 2.2% to 4.4%/year. Their long-term 
9-year follow-up of patients undergoing myectomy 
and patients receiving verapamil treatment showed 
a mortality rate of 0.6%/year, although only 17 
patients were treated in this manner. In a larger 
group of 127 patients undergoing septal myectomy, 
Krajcer and associates 32 reported late mortality of 
0.7%/year. 
Comparison of diverse patient groups from mul- 
tiple institutions in a retrospective manner does not 
allow definitive conclusions regarding the superior- 
ity of one form of treatment over another. Further- 
more, the reported mortality rates with medical and 
surgical therapy variably refer to both cardiac and 
noncardiac deaths. In general the younger the pa- 
tient population the more often late premature 
deaths are due to cardiac causes in contrast to an 
older group such as ours in which late deaths may 
result from a variety of noncardiac causes. Four of 
the eight late deaths in our cases of septal myectomy 
with or without CABG were due to malignancy. 
Given the limitations of a retrospective r view we 
can conclude that our overall operative mortality in 
a symptomatic, diverse group of patients undergoing 
myectomy is acceptably ow and that the rate of late 
cardiac deaths is very low. 
Our multivariate analysis identified late valve 
operation, increasing age, syncope, postoperative com- 
plete heart block, and return to bypass with MVR as 
factors ignificantly associated with late death. 
Syncope is the symptom that has been shown to 
be most strongly associated with the development of 
sudden death in multiple studies that have investi- 
gated relevant risk factors. 1'33 Other identified pro- 
posed risk. factors include young age, increased left 
ventricular wall thickness, a family history of sudden 
death, and nonsustained ventricular tachycardia on 
ambulatory electrocardiographic monitoring. 1 The 
mechanism by which a history of syncope may 
predispose a patient o sudden death is uncertain. 34
Syncope is associated with inducible sustained ven- 
tricular arrhythmias. 35 These arrhythmias may be 
manifestations of the underlying pathologic myocar- 
dial cell disarray and fibrosis seen in hypertrophic 
obstructive cardiomyopathy which subsequently is 
not improved by surgical myectomy. 
The association of complete heart block with late 
death may be a marker for those patients with more 
extensive septal hypertrophy 36'37 who, accordingly, 
require a more aggressive subaortic resection to 
relieve outflow obstruction. The recognized associ- 
ation of this increased septal hypertrophy with sud- 
den death 35 may provide an explanation for our 
findings. Confirmation would require echocardio- 
graphic evidence of increased septal hypertrophy in 
those patients in whom complete heart block devel- 
oped compared with those unaffected (information 
not available from our study). 
The influence of concomitant valve operation on 
late survival was profound. The yearly mortality rate 
in hospital survivors undergoing valve operation was 
6.6%/year--more than 10 times greater than that in 
the septal myectomy with or without CABG group. 
Those patients undergoing valve operation were 
particularly diverse with a variety of cardiac surgical 
diseases that included mitral or aortic valvular dis- 
'ease, hypertrophic obstructive cardiomyopathy, and, 
in 14 patients, concomitant coronary artery disease. 
The small number of patients in each valve category 
does not allow statistical analysis of associated risk 
factors for late death in comparison with other surgical 
subgroups. The adverse impact of valve operation on 
late survival may reflect diastolic dysfunction seen in 
hypertrophic obstructive cardiomyopathy in combina- 
tion with valvular disease. This diastolic dysfunction 
may be even more severe in older patients 3 and 
potentially limits the normal pathophysiologic n- 
creases in myocardial wall thickness and chamber 
dimension that are usual adaptive responses to pres- 
sure and volume loading valvular disease. 
Role of MVR. Those patients with significant MR 
who do not respond to initial myectomy and require 
a return to cardiopulmonary bypass and MVR were 
at significantly higher risk for late death on our 
multivariate analysis. Of the seven patients in this 
category, six had MR grade 3 to 4+ before the 
operation. Of the 60 patients with preoperative MR 
grade 3+ to 4+, 16 required MV replacement, and, 
of those 16, six procedures were performed after an 
attempted myectomy without MVR was inadequate 
to correct the underlying MR. Why this group 
should be at higher risk for late death is unclear. 
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The reason for this increased risk requires an 
understanding of the variable response of existing 
preoperative MR to attempted septal myectomy and 
may be related to our current understanding of the 
pathophysiologic condition of MR in hypertrophic 
obstructive cardiomyopathy. 
Doppler echocardiographic study of dynamic 
LVOT obstruction during systole has provided our 
understanding of the relationship between the mi- 
tral valve and the hypertrophic septum. 1 The Ven- 
turi effect of a high velocity jet through an area of 
9 subaortic septal obstruction appears to direct the 
anterior mitral leaflet toward the septum during 
mid-systole, exacerbating the obstruction, interfer- 
ing with normal mitral valve closure, and producing 
a variable degree of MR. The role of this septal 
hypertrophy and the precise site of SAM-induced 
septal contact provides the morphologic basis for 
our echocardiographic demonstration f the appro- 
priate site for surgical resection. 
The validity of this approach allowed us to suc- 
cessfully reverse MR grade 3+ to 4+ in 44 of 60 
patients with septal myectomy alone. In 10 of the 
remaining 16 patients the underlying preoperative 
mitral valve disease was recognized (subacute bac- 
terial endocarditis n = 3, rheumatic n = 2, cleft 
mitral valve n = 2, myxomatous n = 2, papillary 
fibroelastosis n = l ) ,  and the operating surgeon 
performed mitral valve repair or replacement a the 
initial operation. Five patients required MVR be- 
cause of either a persistent postmyectomy gradient 
or MR. Four of these five had normal mitral valves, 
and one had a redundant posterior mitral leaflet. 
Two patients required reoperation and MVR during 
initial hospitalization for persistent postoperative 
MR, and both of these patients were found to have 
apparently normal mitral valves. This experience 
suggests that a small subgroup of patients, despite 
myectomy, have persistent MR with no clearly iden- 
tified mitral valve disease. In addition, this subgroup 
after MVR appears to be at higher risk for late 
death. 
The concept of systolic anterior motion of the 
anterior mitral leaflet as a cause of MR emphasizes 
the role of septal disease rather than potential 
underlying mitral valve disease. A small number of 
patients have intrinsic mitral valve disease, usually 
recognized before the operation, in combination 
with hypertrophic obstructive cardiomyopathy. In
addition, a separate group of patients may have 
more subtle mitral valve abnormalities combined 
with septal hypertrophy. Recent pathoanatomic 
studies have shown that, in addition to the charac- 
teristic asymmetric obstructing septal hypertrophy, 
intramural coronary artery anomalies, and myocar- 
dial fibrosis characteristic of hypertrophic obstruc- 
tive cardiomyopathy, many patients have associated 
complex mitral valve abnormalities. 1 These include 
increased mitral valve surface area, asymmetry in 
scallop configuration, chordal rupture, 39 abnormal 
papillary muscle insertion, 4~ and anterior displace- 
ment of the mitral valve. Klues and associates 41have 
shown this spectrum of structural malformations in
66 of 94 explanted mitral valves from patients with 
hypertrophic cardiomyopathy. These studies uggest 
that the morphologic definition of hypertrophic ob- 
structive cardiomyopathy may need to be expanded 
to include the mitral valve. They also emphasize the 
potential complex role of the mitral valve in combi- 
nation with septal hypertrophy in producing MR. 
Understanding this subgroup of patients with appar- 
ently "normal" mitral valves before the operation 
and who subsequently require MVR after initial 
myectomy may help to elucidate why this group is at 
higher risk for late death. 
Our study does not resolve the ongoing contro- 
versy over the role of MVR in hypertrophic obstruc- 
tive cardiomyopathy. 43-4s Currently the National 
Institutes of Health group 47 recommends MVR (1) 
in the presence of a thin septum <18 ram, (2) in the 
presence of atypical septal structure, (3) after pre- 
vious septal myectomy, and (4) when intrinsic mitral 
valve disease is present. This approach as led to 
25% of their patients requiring MVR. Krajcer and 
associates 46 have long emphasized the excellent 
hemodynamic results of primary MVR in patients 
with severely symptomatic hypertrophic obstructive 
cardiomyopathy and have performed MVR in 29% 
of hypertrophic obstructive cardiomyopathy cases in 
the presence of either severe MR or after failure of 
septal myectomy. Walker and associates 43have rec- 
ommended primary MVR for hypertrophic obstruc- 
tive cardiomyopathy b  less experienced units be- 
cause it provides a more consistent reduction in the 
LVOT gradient. However, the recognized bleeding, 
infectious and thromboembolic risks of prosthetic 
MVR, our excellent long-term results of myectomy 
alone, and the finding that valve operation itself is a 
risk factor for late death lead us to continue to 
recommend myectomy as the primary treatment for 
hypertrophic obstructive cardiomyopathy. Patients 
with intrinsic mitral valve disease are best treated 
with MVR. The small group of patients who have 
persistent MR after septal myectomy and who ap- 
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pear to have structurally normal valves on preoper- 
ative echocardiography are a difficult group. A 
better understanding of the exact mechanism of 
regurgitation i these valves may allow more precise 
future treatment recommendations. 
The role of mitral valve repair is not dearly defined, 
but our anecdotal experience suggests that the results 
of repair are less predictable in the presence of signif- 
icant hypertrophic cardiomyopathy. 
Functional improvement. Symptomatic mprove- 
ment in our diverse patient population was excel- 
lent. No risk factors could beidentified that allowed 
us to predict treatment failure in this group. Seven 
percent of patients who underwent operation were 
in functional class III or IV on long-term follow-up. 
Comparable objective functional improvement after 
myectomy has been reported in other surgical se- 
riesJ' 25 Our findings further establish the efficacy of 
surgical myectomy in reducing the symptoms of hyper- 
trophic obstructive cardiomyopathy. Objective im- 
provement in exercise tolerance and maximal oxygen 
consumption, 49 improvements in thallium perfusion, 5~ 
improvements in myocardial metabolism, 51 and reduc- 
tion in LV hypertrophy 52 provide objective correlates 
of this observed clinical improvement. 
Conclusion 
Our retrospective r view of this diverse group of 
patients hows that (1) transaortic septal myectomy 
provides effective symptom relief with low operative 
mortality and low risk of late cardiac death, (2) 
increasing age and preoperative amiodarone usage 
are strong predictors of perioperative mortality, (3) 
increasing age, postoperative complete heart block, 
valve operation, a history of syncope , and the need 
for MVR after return to cardiopulmonary b pass at 
initial operation adversely influences long-term sur- 
vival, and (4) the majority of patients with significant 
MR before operation are effectively treated with 
septal myectomy alone, although a difficult minority 
of cases not regularly identified before surgery will 
require prosthetic MVR to control the MR and 
LVOT gradient in hypertrophic obstructive ear- 
diomyopathy. 
We thank Deborah Gladish for her assistance with data 
collection and project management. 
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Discussion 
Dr. William G. Williams (Toronto, Ontario, Canada). I
congratulate Dr. Herie and his colleagues for focusing our 
attention on the mitral valve in hypertrophic obstructive 
cardiomyopathy. And I rise to add substantive evidence to 
his data which illustrate the success of septal myectomy 
alone in dealing with the mitral incompetence in this 
disease. 
Intraoperative transesophageal echocardiography 
shows clearly the mechanism of the mitral incompetence. 
The basis of the disease, as has been outlined, is the 
thickening of the intraventricular septum which narrows 
the subaortic hannel. As shown with color Doppler, the 
narrowed channel results in flow acceleration and turbu- 
lence in the subaortic area, and that flow acceleration 
drags the mitral valve toward the intraventricular septum, 
the so-called systolic anterior motion. As a result of the 
displacement of the valve, the leaflets fail to coapt and 
there is MR, which is typically posteriorly directed and 
occurs late in systole. It is important hat the degree of 
outlet obstruction correlates with the degree of mitral 
incompetence. And when it does not, it indicates that 
there is independent mitral valve disease which must be 
addressed. 
After myectomy, the intraoperative echocardiography 
shows a widening of the outflow tract and a loss of 
turbulence in the subaortic area, and consequently the 
valve closes in a normal plane, coapts properly, and 
eliminates or certainly reduces the mitral incompetence. 
Our experience with the surgical treatment of hypertro- 
phic cardiomyopathy consists of 189 patients. In 78% the 
lesion was isolated, although I hasten to add that all of 
these patients had some degree of mitral incompetence, 
usually mild or moderate, but in a few, severe. 22% of the 
patients had other concomitant lesions, but note that 
independent MR was present in only four patients, and in 
all it was dealt with by valve repair. In no patient was 
MVR required. 
There are four operative deaths in this series, including 
one in the 174 patients who had an isolated myectomy. To 
date there are nine late deaths. Ten-year survival of 84% 
is similar to survival in your series. Importantly, no patient 
has required reoperation for mitral valve disease. 
Our experience concurs with Dr. Heric's data in recom- 
mending that the mitral valve repair or replacement is
seldom necessary inpatients with hypertrophic obstructive 
cardiomyopathy. Subaortic myectomy alone restores mi- 
tral valve function. 
I have a question for Dr. Heric regarding the amount of 
muscle excised. I think it is important o excise enough 
myocardium to eliminate the LVOT gradient both at rest 
and with provocation. We try to excise an area equivalent 
to the area of the aortic root. Do you have any data 
regarding the amount of muscle excised, particularly in 
that group of patients who you return to bypass to resect 
additional muscle? 
I enjoyed your paper and presentation and thank you 
for the interesting data. 
Dr. Herlc. First, let me make a comment on your 
statements about the utility of performing myectomy in 
relieving significant MR. We looked at 60 of our patients 
who came to the operating room with documented 2+ to 
3+ MR, and indeed, as you have shown, 44 of those 
patients who underwent isolated myectomy had complete 
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resolution of their MR. This concurs with our understand- 
ing of the pathophysiologic aspects of MR in this disease. 
However, 8 of the remaining 16 patients who, despite 
having what appeared to be adequate myectomy as doc- 
umented by echocardiography, still had persistent MR. Six 
of them underwent MVR at initial operation because of 
persistent MR, and two patients underwent MVR in the 
postoperative p riod. The other eight patients had intrin- 
sic mitral valve disease that was apparent before the 
operation and actually underwent MVR initially, as 
planned. 
I would agree that myectomy is effective for the vast 
majority of patients who have MR in association with 
hypertrophic obstructive cardiomyopathy and would also 
agree that patients who have what appears to be intrinsic 
mitral valve disease will require some type of mitral valve 
procedure. H6wever, I believe there is a group of patients 
with hypertrophic obstructive cardiomyopathy who ap- 
pear to have normal mitral valves before the operation 
who after myectomy do not improve and experience 
persistent MR. 
I think this is a subgroup of patients that we do not 
understand completely. There is an increasing amount of 
literature documenting that, in fact, the mitral valve in 
hypertrophic cardiomyopathy that appears to be normal 
before the operation may be significantly pathologic. 
Pathoanatomic studies show that these mitral valves are 
indeed abnormal. The mitral valve may have a role in MR 
that is separate and more complex than the mechanistic 
role of systolic anterior motion alone. 
To answer your question about the amount of muscle 
that was removed, we did not document the amount of 
muscle removed at  myectomy. Every surgeon had a 
slightly different approach to this operation and did not 
routinely weigh the specimen. We were dependent on 
echocardiography to basically document he necessary 
extent of resection and the precise volume of resection 
that would relieve the source of outflow obstruction. 
Dr. Hagen D. Schulte (Dusseldorf,, Germany). You 
showed 32 patients who had to undergo remyectomy. We 
had the same experience in our earlier series and there- 
fore we extended our incision from the original Morrow 
procedure to a Bigelow incision. And also the excision was 
continued own to the baseline of the papillary muscles. 
And so I support he remarks of Dr. Williams that you 
have to extend the myectomy, 
My first question is, did you only rely on echocardiog- 
raphy or did you also do pressure measurements simulta- 
neously during the operation? 
My second question is related to the amount of patients 
with total atrioventricular block after operation. Do you 
have any idea what the reason for this is, except in those 
patients who had previous right bundle branch block? 
Dr. Heric. If I understand your second question, you 
were wondering why we had such a high incidence of 
complete heart block? 
Dr. Schulte. What is the reason? 
Dr. Heric. To answer your second question first, we 
were also impressed with the frequency of complete heart 
block. It developed in 10% of our entire patient group, 
which is twice the generally reported 5% incidence. 
Six of the cases of complete heart block actually oc- 
curred in that more complex group who had concomitant 
valve operations. Looking at the myectomy group alone, 
there were only 10 patients in whom complete heart block 
developed, an incidence of 6%. We found a significant 
association between areturn to cardiopulmonary b pass, a
more extensive myectomy and the development of com- 
plete heart block. 
I believe the incidence of complete heart block in our 
series was a consequence of being fairly rigorous about 
requiring an adequate result after initial myectomy as 
determined by the echocardiographers, who are insistent 
that we do so. 
And as a consequence of doing what we think is a more 
thorough myectomy, we have a slightly increased inci- 
dence of complete heart block. This is somewhat prob- 
lematic. We would like to think that the thorough degree 
of myectomy isassociated with our good long-term results, 
but, in fact, we have shown that complete heart block is a 
risk factor for late mortality. I cannot resolve whether this 
aggressive approach is correct, but I think the return to 
bypass for increasing myectomy was associated with our 
higher incidence of complete heart block. 
We generally, in the early portion of the experience, did 
direct measurements in the ventricle and in the aorta to 
document he LVOT gradient. As we became more 
comfortable and familiar with intraoperative echocardiog- 
raphy and because our cardiologists have an interest in 
this disease, we have relied on echocardiography to estab- 
lish the LVOT gradients. 
Dr. Bruno J. Messmer (Aachen, Germany). Dr. Heric, I 
congratulate you on an honest paper, demonstrating also 
all the ,complications that can appear. 
Some 15 years ago we modified the original Morrow 
technique. First we insert a sharp triple hook into the left 
ventricle to pull at the deepest point of the septal muscle 
bulge. By this maneuver and cutting in front of the prongs, 
the muscle bulge can be excised over its whole long axis. 
With the traditional Morrow technique the deepest point 
is often not reached, which may result in residual obstruc- 
tion. 
The second major modification consists in liberal mo- 
bilization of both papillary muscles from lateral attach- 
ments to the left ventricular wall and from hypertrophic 
interpapillary trabeculae. If necessary we trim the papil- 
lary muscles to slim sugar hats. It is important to reach full 
mobilization of the subvalvular apparatus of the mitral 
valve. 
Since 1979 this technique has been used in 59 patients 
with one early death caused by multiorgan failure. Sur- 
vival at 10 years is 85%. Postoperative echocardiographic 
studies how either a fully competent valve or only trivial 
insufficiency in spite of the fact that one third of the 
patients had 2+ and 3+ mitral insufficiency before oper- 
ation and nothing had been done to the mitral valve itself 
with the exception of generous mobilization of the papil- 
lary muscles. In your presented paper, you have 16 
patients with persistent mitral insufficiency, and I suspect 
that this is due to noncorrected malattachment and hy- 
pertrophy of the papillary muscles. Did you have a chance 
to inspect he papillary muscles during the operation? 
Furthermore can you provide us some late noninvasive 
or invasive dates on your patients? In our series we have 
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done postoperative invasive studies in 22 unbiased survi- 
vors (39%). The average gradient at rest fell from 79 mm 
Hg before the operation to 5 mm Hg after the operation 
with the gradient under stress decreasing from 147 to 16 
mm Hg. Finally, I wonder if your group has any experi- 
ence with simple insertion of a DDD pacemaker system 
without myectomy in patients with hypertrophic obstruc- 
tive cardiomyopathy? 
Dr. Herie. To answer your first question, generally, 
when performing the myectomy, the incision is extended 
toward the LV apex until the papillary muscles are 
visualized. That is part of the operative procedure that all 
of the involved surgeons perform. I cannot make any 
comment about the appearance of the papillary muscles 
or their potential involvement in persistent MR by vari- 
able operating surgeons who were doing the procedures at 
the time. 
I would also comment hat our understanding of the 
disease of hypertrophic obstructive cardiomyopathy 
should include more than just the interventricular septum. 
The pathologic studies I previously mentioned have 
shown abnormal attachments between the papillary mus- 
cles and the mitral apparatus that are potentially impor- 
tant in the development of MR. Your procedure might be 
directed against this pathology, I do not know. We did not 
do this procedure, and I do not have any Other specific 
comments. 
Regarding late echocardiographic follow-up, our pa- 
tients were variably followed up. On late follow-up, only 
one patient underwent MVR and no patients underwent 
late redo myectomy. All the patients who were in our 
geographic area were followed up with echocardiography, 
and none of them had significant postoperative gradients 
that were .brought o our attention. However, because 
echocardiographic follow-up of these patients was incon- 
sistent, we have not reported on this aspect of follow-up. 
We will attempt more complete echocardiographic fol- 
low-up as a future project. 
There is a recent experience with DDD pacemakers for 
hypertrophic obstructive cardiomyopathy at our institu- 
tion that actually has occurred since I have left the 
institution. Our study only included patients to early 1993, 
so I cannot comment on our recent experience with DDD 
pacemaker therapy. 
Dr. Khalid Rasheed (Riyadh, Saudi Arabia). Our expe- 
rience with similar cases has been that, after coming off 
cardiopulmonary b pass, there is often a significant gra- 
dient across the outflow tract. Most of this gradient is due 
to dynamic obstruction secondary to hypertrophy of the 
left ventricle. If the gradient is again checked after 15 to 
20 minutes there is already a sharp fall in it and in some 
patients in whom we have repeated these measurements 
once again just before closing the chest; to our surprise, 
the gradient had almost completely disappeared. 
My question is whether you also do repeated measure- 
ment of the gradient because, in my opinion, this would 
probably have saved some patients from reoperation. 
Also, transesophageal echocardiograpby alone would 
probably have a higher chance of error because of the 
dynamic element of obstruction. 
Dr. tIeric. Every surgeon's approach to this disease was 
somewhat different. I think every surgeon is naturally 
reluctant o go back on bypass and do another surgical 
procedure. I would say, in general, although I do not have 
data to show you, surgeons were reluctant and wanted to 
see persistent real gradients, real systolic anterior motion, 
and real MR after initially coming off bypass with admin- 
istration of isoproterenol (Isuprel) to be convinced of the 
need for extended remyectomy. 
I was interested in whether those patients who, despite 
having a persistent gradient, MR, or systolic anterior 
motion that we would generally find unacceptable in the 
operating room had any long- or short-term morbidity. 
Because, obviously, this issue is of importance to sur- 
geons, your approach suggesting that by ignoring these 
echocardiographic abnormalities patients my do well after 
initial myectomy. I found on follow-up of this group of 
patients, as I pointed out in my talk, that none of them had 
any adverse vents either in hospital or later. So I was not 
able to show that having moderate MR or systolic anterior 
motion and having a provokable gradient had any long- 
term adverse ffect, so perhaps your approach is reason- 
able. 
Appendix A. Late events 
No. of Total 
Event patients events 
Ventricular arrhythmias 22 39 
Catheterization 13 16 
Congestive heart failure 9 13 
Return of New York Heart 9 12 
Association functional 
class III or IV 
Reoperation 6 7 
Cerebrovascular ccident 4 4 
Percutaneous transluminal 3 7 
coronary angioplasty 
Myocardial infarction 3 4 
Permanent pacemaker 2 2 
Thromboembolic 1 1 
Endocarditis 1 1 
Wound complication 1 1 
Respiratory 1 1 
None 74 0 
